IRIDEX Corporation (IRIX) is a Medical - Devices company in the Healthcare sector, currently trading at $1.03. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is IRIX = $3 (+191.3% upside).
Valuation: IRIX trades at a trailing Price-to-Earnings (P/E) of -3.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.03.
Financials: revenue is $53M, -2.3%/yr average growth. Net income is $4M (loss), growing at +10.1%/yr. Net profit margin is -8.4% (negative). Gross margin is 36.7% (-7.8 pp trend).
Balance sheet: total debt is $5M against $5M equity (Debt-to-Equity (D/E) ratio 0.92, moderate). Current ratio is 1.91 (strong liquidity). Debt-to-assets is 15.5%. Total assets: $29M.
Analyst outlook: 3 / 4 analysts rate IRIX as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 75/100 (Pass), Moat 21/100 (Fail), Future 85/100 (Pass), Income 10/100 (Fail).
